We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
The upcoming report from Moderna (MRNA - Free Report) is expected to reveal quarterly loss of $1.91 per share, indicating a decline of 37.4% compared to the year-ago period. Analysts forecast revenues of $1.25 billion, representing a decrease of 31.7% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Moderna metrics that are routinely monitored and predicted by Wall Street analysts.
It is projected by analysts that the 'Revenue- Product sales' will reach $1.21 billion. The estimate indicates a year-over-year change of -31.3%.
Analysts predict that the 'Revenue- Other revenue' will reach $16.30 million. The estimate points to a change of -78% from the year-ago quarter.
According to the collective judgment of analysts, 'Product sales- Rest of world' should come in at $362.69 million. The estimate indicates a year-over-year change of -51.1%.
Analysts expect 'Product sales- United States' to come in at $728.42 million. The estimate points to a change of -20.2% from the year-ago quarter.
Shares of Moderna have demonstrated returns of -9.3% over the past month compared to the Zacks S&P 500 composite's +0.4% change. With a Zacks Rank #3 (Hold), MRNA is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
The upcoming report from Moderna (MRNA - Free Report) is expected to reveal quarterly loss of $1.91 per share, indicating a decline of 37.4% compared to the year-ago period. Analysts forecast revenues of $1.25 billion, representing a decrease of 31.7% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Moderna metrics that are routinely monitored and predicted by Wall Street analysts.
It is projected by analysts that the 'Revenue- Product sales' will reach $1.21 billion. The estimate indicates a year-over-year change of -31.3%.
Analysts predict that the 'Revenue- Other revenue' will reach $16.30 million. The estimate points to a change of -78% from the year-ago quarter.
According to the collective judgment of analysts, 'Product sales- Rest of world' should come in at $362.69 million. The estimate indicates a year-over-year change of -51.1%.
Analysts expect 'Product sales- United States' to come in at $728.42 million. The estimate points to a change of -20.2% from the year-ago quarter.
View all Key Company Metrics for Moderna here>>>
Shares of Moderna have demonstrated returns of -9.3% over the past month compared to the Zacks S&P 500 composite's +0.4% change. With a Zacks Rank #3 (Hold), MRNA is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>